Patents by Inventor Sarit Samira

Sarit Samira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180244778
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Application
    Filed: May 14, 2018
    Publication date: August 30, 2018
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Patent number: 10000567
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 19, 2018
    Assignee: Therapix Biosciences Ltd.
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Patent number: 9879076
    Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 30, 2018
    Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Sarit Samira, Nurit Rachamim, Michael Tal, Ronald Ellis, Idan Rakover, Rom E. Eliaz, Beka Solomon, Timothy David Jones, Francis Joseph Carr, Polina Rabinovich-Toidman, Meital Sooliman
  • Publication number: 20160017025
    Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Inventors: Sarit SAMIRA, Nurit RACHAMIM, Michael TAL, Ronald ELLIS, Idan RAKOVER, Rom E. ELIAZ, Beka SOLOMON, Timothy David JONES, Francis Joseph CARR, Polina RABINOVICH-TOIDMAN, Meital SOOLIMAN
  • Publication number: 20150175699
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Application
    Filed: March 12, 2013
    Publication date: June 25, 2015
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Patent number: 7906122
    Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection. Other aspects of the invention concern methods for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection, by the use of the sphingoid-polyalkylamine conjugate, complexes comprising the sphingoid-polyalkylamine conjugate and a biologically active molecule, the latter, having an effect of stimulating or enhancing an immune response of a subject against to protect Hepatitis B Virus (HBV) infection, as well as kits making use of said conjugates and complexes. A preferred conjugate according to the invention is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 15, 2011
    Assignees: Yissum Research Development Company of the Hebrew University of Jersusalem, Biolab Ltd., Nasvax Ltd.
    Inventors: Yechezkel Bareholz, Eliezer Kedar, Sarit Samira
  • Publication number: 20070264273
    Abstract: The present application discloses methods for stimulating or enhancing an immune response of a subject to protect against an infection caused by an agent selected from Hepatitis B Virus (HBV), avian influenza virus, the bacterium Bacillus anthracis or the bacterium Streptococcus pneumoniae, the method comprising administering to said subject a combination of sphingoid-polyalkylamine conjugate and a biologically active molecule, the combination being effective to provide said stimulation or enhancement of the immune response. Also disclosed are vaccines comprising a combination of the sphingoid-polyalkylamine conjugate and a biologically active molecule for stimulating or enhancing an immune response of a subject to protect against an infection caused by such an agent. Preferred conjugates are N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (C-1 CCS), N-palmitoyl D-erythro sphingosyl-3-carbamoyl spermine (C-3 CCS) and mixtures thereof. Also disclosed are uses of C-3 CCS for various applications.
    Type: Application
    Filed: May 9, 2007
    Publication date: November 15, 2007
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, BioLab Ltd., NasVax Ltd.
    Inventors: Yechezkel BARENHOLZ, Eliezer Kedar, Sarit Samira
  • Publication number: 20060171956
    Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection. Other aspects of the invention concern methods for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection, by the use of the sphingoid-polyalkylamine conjugate, complexes comprising the sphingoid-polyalkylamine conjugate and a biologically active molecule, the latter, having an effect of stimulating or enhancing an immune response of a subject against to protect Hepatitis B Virus (HBV) infection, as well as kits making use of said conjugates and complexes. A preferred conjugate according to the invention is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).
    Type: Application
    Filed: February 2, 2006
    Publication date: August 3, 2006
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, BIOLAB LTD., NasVax Ltd.
    Inventors: Yechezkel Bareholz, Eliezer Kedar, Sarit Samira